
Scegli la tua etichetta
mostrata direttamente sul flaconcinoReta + Tesamorelin Blend
GLP-1
- Spedito dalla Germania
Ordine
- DHL con tracciamento
- Imballaggio discreto
In sintesi
Reta + Tesamorelin Blend in cifre
I dati chiave dalla nostra enciclopedia.
Voce completa dell'enciclopedia- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Recensioni
Cosa dicono i clienti
Solo ordini reali che includevano Reta + Tesamorelin Blend.
Tutte le recensioniNon esiste ancora un'analisi di laboratorio per Reta + Tesamorelin Blend. Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio
Conoscenze
Tutto su Reta + Tesamorelin Blend
Informazioni dettagliate in arrivo.
Dosaggio
Caricamento informazioni sul dosaggio …
Utili da avere
Cosa ti serve insieme
L'acqua batteriostatica viene aggiunta automaticamente al carrello. Siringhe e tamponi con un clic.
Siringhe da insulina
10 pz · 5.50 €
Tamponi imbevuti di alcol
50 pz · 10 €
Quanta acqua?
Unità sulla siringa per la misura del tuo flaconcino.
Apri il calcolatore →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Correlati
Prodotti correlati
Tirzepatide
Peptidi · GLP-1 e perdita di grasso GLP-1 e perdita di grasso
10 misure
Testato in laboratorio
= da 10 €/fiala
Retatrutide
Peptidi · GLP-1 e perdita di grasso GLP-1 e perdita di grasso
11 misure
Testato in laboratorio
= da 16 €/fiala
Semaglutide
Peptidi · GLP-1 e perdita di grasso GLP-1 e perdita di grasso
6 misure
Testato in laboratorio
= da 10 €/fiala
Mazdutide
Peptidi · GLP-1 e perdita di grasso GLP-1 e perdita di grasso
2 misure
= da 32 €/fiala
Reta + Tesamorelin Blend